Enterprise Innovation

Translating Research into Next Generation Care Through Collaboration

Based in New York City, Weill Cornell Medicine Enterprise Innovation engages and collaborates with Weill Cornell Medicine faculty and trainees while fostering alliances with leaders in the biomedical industry and business and investment community. Our focus is to translate the application of emerging science and new technologies into world-class medical breakthroughs.

Integrating Weill Cornell Medicine’s different teams and resources under a single, united organization, Enterprise Innovation encompasses the entire spectrum of an effective innovation ecosystem. We offer unique opportunities for faculty and trainees to transform their research into medical advances through collaborations including access to the Sanders Tri-Institutional Therapeutics Discovery Institute.

Read More About Us

Enterprise Innovation Metrics from FY18 to FY23

520
New Tech Disclosures
183
Issued US Patents
152
Licenses and Options
29
NewCo Launches
Two researchers in PPE doing experiment
For Inventors and Innovators
Learn about how to collaborate with our team of top-tier business development professionals to bring your innovations to life.
Two men in dark blue suits shaking hands and two women at the table smiling
For Industry, Investors and Partners
Learn about groundbreaking innovations you can partner to fuel a pipeline or launch a new venture.

  

A Caucasian and an Indian woman holding some booklets and talking
Innovation Ecosystem
Learn more about the infrastructure and different components of Enterprise Innovation.
Four medical students in white coats sitting at a table and listening to a lecture
Programs, Offerings and Support
Explore entrepreneurial programming and education offered by Enterprise Innovation and our ecosystem partners.

  

Technology Portfolio

Enterprise Innovation brings together the power of industry-leading translational research and clinical care combined with top-tier business development expertise to accelerate innovation to market. Our leading technology portfolio encompasses major pillars of biomedical innovation.

  

Two doctors and two business reps talking
Collaboration Opportunities
Check out our available research opportunities for potential collaborations.

  

Events

Bayer logo and the title
Oct 21,2024
11:00am to 12:00pm
Bayer's Expert Mondays Webinar: Partnering with Academia from the
A yellow circle behind the New York City skyline in blue
Oct 22,2024
9:00am to 11:45pm
New York Area Life Science Innovation Bootcamp Fall 2024
A Hispanic woman in a white coat and blue vinyl gloves holding a test tube
Oct 22,2024
12:00pm to 12:45pm
NSF I-Corps Information Session
African-American man wearing a black suit and gray tie and smiling
Oct 22,2024
2:00pm to 4:00pm
Center for Technology Licensing at WCM Office Hours with Eric

Testimonials

Dr. John Leonard
John P. Leonard, M.D., Senior Associate Dean of Innovation and Initiatives
Getting new innovations across the finish line requires collaboration, often with industry partners, to scale up findings for application in healthcare. Ultimately, we want the work we do here to have a real impact on patients. By fostering an entrepreneurial environment, we can do that.
Lisa Placanica, Ph.D.
Lisa Placanica, Ph.D., Senior Managing Director of the Center for Technology Licensing
There’s obviously fantastic research being done at Weill Cornell Medicine. So we want to work with faculty to identify aspects of their research that could be shaped into a product or a service, work with them to develop it and then to forge the partnership with a commercial entity. We also have to have a finger on the pulse of what industry is looking for: what venture firms are investing in, what pharma is trying to fill their pipeline with. And then we make connections between the two. We have to speak the language between the commercial enterprise and the academic researcher.
Randi Silver, Ph.D.
Randi B. Silver, Ph.D., Associate Dean and Professor of Physiology and Biophysics
Enterprise Innovation has galvanized us to move forward as basic scientists, and to look for translational aspects that could be developed, with an industrial partner, for patient care. As a result, we have been able to get traction in exploring various avenues for commercialization with angel investors, pharma, venture capital and, significantly, our own Tri-Institutional Therapeutics Discovery Institute, none of which would have been possible without support from the Daedalus Fund for Innovation.
Dr. Ronald Crystal
Ronald G. Crystal, M.D., Chair of Genetic Medicine and Professor of Medicine
Allying with the right industrial partner is a vital factor in attracting investors, and Enterprise Innovation’s relationships with and access to biopharma and life science leaders make it possible for aspiring scientist/entrepreneurs to find the right match.

News

A triple-negative breast cancer cell

New Genetic Signatures Can Classify Breast Cancers and Guide Prognosis

October 4, 2024

Researchers at Weill Cornell Medicine have developed breast cancer cell-of-origin signatures that can better predict both overall and progression-free survival of patients with breast cancer compared to previously developed genomic signatures.
A Caucasian man in white coat

The Englander Institute for Precision Medicine Receives Gift from Investment Firm to Support Its Innovative Cancer Therapeutic Research

October 4, 2024

The Medical Excellence Foundation (MEF) pledged to Weill Cornell Medicine a two-year, $200,000 philanthropic gift to support the work of Dr. Olivier Elemento, director of the Englander Institute for Precision Medicine (EIPM) and a professor of physiology and biophysics.